Page last updated: 2024-08-21

eriodictyol and Lung Injury, Acute

eriodictyol has been researched along with Lung Injury, Acute in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Deng, R; Dong, J; Huang, L; Li, J; Wang, X; Zhang, B	1

Other Studies

1 other study(ies) available for eriodictyol and Lung Injury, Acute

Article	Year
Eriodictyol ameliorates lipopolysaccharide-induced acute lung injury by suppressing the inflammatory COX-2/NLRP3/NF-κB pathway in mice. Journal of biochemical and molecular toxicology, 2020, Volume: 34, Issue:3 Topics: Acute Lung Injury; Animals; Cyclooxygenase 2; Flavanones; Inflammation; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction	2020

Article

Year

Eriodictyol ameliorates lipopolysaccharide-induced acute lung injury by suppressing the inflammatory COX-2/NLRP3/NF-κB pathway in mice.

Journal of biochemical and molecular toxicology, 2020, Volume: 34, Issue:3

Topics: Acute Lung Injury; Animals; Cyclooxygenase 2; Flavanones; Inflammation; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction

2020